ID
17654
Beschreibung
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Open-label Tarceva Consent and Eligibility
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Stichworte
Versionen (2)
- 02.08.16 02.08.16 -
- 27.09.16 27.09.16 -
Hochgeladen am
27. September 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Open-label Tarceva, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Beschreibung
Open-label Tarceva Eligibility
Beschreibung
Open-label Tarceva Eligibility
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1516637
Beschreibung
Eligibility Criteria: OSI-774-302 Protocol Version 2, 21 November 2007, Appendix 12.9
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1302261
Beschreibung
Eligibility Criteria
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1516637
Beschreibung
Eligibility Criteria
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1516637
Beschreibung
Eligibility Criteria
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1516637
Beschreibung
Eligibility Criteria
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1516637
Beschreibung
Exemption
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348482
Beschreibung
Investigator Signature
Beschreibung
I have reviewed all data for this patient's eligibility and confirm that consent has been obtained in accordance with the GCP Directive (2005/28/EC) or EU Directive (2001/20/EC) and other applicable GCP requirements.
Datentyp
text
Alias
- UMLS CUI [1]
- C2346576
Beschreibung
Investigator Signature Date
Datentyp
date
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Ähnliche Modelle
Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C1135136 (UMLS CUI [1,2])
C2348482 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])